




PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE ANTHRACYCLINES

Field of the invention


The present invention refers to a process for the synthesis of optically active anthracyclines wherein the optically active key intermediate (R) 2-acetyl-2-hydroxy-1,2,3,4-tetrahydronaphthalene 5,8-dialkoxy of formula I.




wherein: R = C₁₋₃ alkyl, preferably methyl.

is prepared starting from 5,8-dialkoxy-3,4-dihydronaphthalene by acylation, asymmetric dihydroxylation, transformation into chloroacetate dehydrochloridation and final hydrolysis.

The invention refers also to the intermediates of formula V e VI:



V




VI

Having an enantiomeric excess higher than 95%.

State of the art


As it is known the anthracyclines of formula VIII



VIII

Wherein: R₁ = H, OH, OCH₃; R₂ = H, OH; R₃ = X, Y o Z where






are compounds having a wide therapeutic use as anti-neoplastic drugs.

Known compounds of formula VIII having the above said properties are for
 5 example Daunomicin (VIII, wherein: $R_1 = \text{OCH}_3$, $R_2 = \text{H}$, $R_3 = \text{X}$), Ia Doxorubicin
 (VIII wherein: $R_1 = \text{OCH}_3$, $R_2 = \text{OH}$, $R_3 = \text{X}$), l'Hydrarubicin (VIII wherein: $R_1 = \text{H}$,
 $R_2 = \text{H}$, $R_3 = \text{X}$) e l'Epirubicin (VIII wherein: $R_1 = \text{OCH}_3$, $R_2 = \text{OH}$, $R_3 = \text{Y}$), or the
 compounds described in EP721456, in particular the compound of formula VIII
 wherein $R_1 = \text{H}$, $R_2 = \text{OH}$, $R_3 = \text{Z}$, disaccharide anthracycline which is now under
 10 clinical development.

The synthesis of anthracycline of formula VIII requires many steps and is normally
 performed starting from an optically active tetraline of formula I which is reacted by
 a Friedel-Crafts reaction with phthalic anhydride or its derivatives as phthaloyl
 dichloride or phthaloyl chloride methylester and thereafter cyclised. The so
 15 obtained tetracycle is protected in the 13-oxo position with ethylenglycol, is
 brominated in position 7 and converted into a 7-OH derivative with known methods
 (see Arcamone et al. , *Experientia*, 1978,34,1255; Wong et al. *Can. J. Chem.*,
 1971, 49, 2712; Swenton et al. , *Tetrahedron*, 1984, 40, 4625). After deprotection
 the anthracyclinone of formula VII (wherein $R_2 = \text{H}$) is used as such or is converted
 20 into a 14 acyloxy derivative (compound of formula VII wherein $R_2 = \text{O-}$
 acyl) according to known procedures.. Thereafter the compounds of formula VII are
 glycosidated with protected mono- or disaccharides as described in literature (see
 Arcamone et al., *Experientia*, 1978, 34, 1255; Terashima et al., *Bull. Chem. Soc.*
Jpn, 1986, 59, 423) and in EP6, by deprotection the anthracycline of formula
 25 VIII are obtained.

In the above described process, or in other similar processes which include as
 intermediate a tetraline, the key intermediate is the tetraline of formula I itself as
 above defined.

This AB synthon (Wong et al. Can. J. Chem, 1971, 49, 2712) allows the formation of the corresponding optically active anthracyclinone of formula VII wherein $R_1 = H, OH, OCH_3$ and $R_2 = H, OH, O\text{-acyl}$ wherein the acyl group is chosen among formyl, acetyl, mono-, di- or trichloroacetyl, preferably acetyl.



As above said the compound is finally converted in the desired anthracycline.

The stereochemistry of position C-9 of the anthracyclinone is very important for the biological activity of these compounds since only the compounds having (S) configuration in C-9 show an antitumour activity.

Therefore also the tetraline intermediate of formula I must obviously possess the same stereochemistry (i.e. an absolute configuration R).

The tetraline I is normally prepared. According to the literature, as a racemic mixture starting from 2-acetyl-5,8-dimethoxy tetraline III by oxydriation in position C-2 with potassium t-butoxide/t-butanol in the presence of oxygen followed by reduction "in situ" (Wong et al., Can. J. Chem., 1971, 49, 2712 ; Gardner et al., J.Org. Chem.1968, 33, 3294).

The compound III was prepared, with very low yields by reacting 5,8-dimethoxy-3,4-dihydronaphthalene II with N-N-diphenylacetamide- $POCl_3$ applying the conditions of the Vilsmeier-Haack reaction followed by the reduction of the double bond.

Several attempts of acylating compound II have been reported but all unsuccessful (Rama Rao et al. Ind.J.Chem.1985, 24B, 697).

Alternatively the compound III was prepared with a yield of about 50% in 4 steps by reaction of 5,8-diacetoxy-3,4-dihydronaphthalene with acetyl chloride/ $AlCl_3$ and formation of a chloroacetyl derivative, followed by dehydrochloridation with LiCl, hydrolysis and methylation "in situ" (Russell et al. J. Chem. Soc. Chem. Comm. 1983, 994).

Another reaction path for obtaining the precursor III reported in literature includes five steps starting from 5,8-dihydroxy-1,4-dihydronaphthalene with a total yield of about 50% (Giles et al. S.Afr.J.Chem, 1990, 43, 87).

The racemic tetraline I is thereafter converted into the pure enantiomeric compound using the normal methods applied for the resolution of racemes through diastereoisomeric Schiff bases on the acetyl lateral chain with (-)-1-phenylethylamine (Arcamone et al. BP 02691/75, 1975). Alternatively the enantiomeric pure compound was prepared by Kinetic resolution via a Sharpless asymmetric epoxidation followed by oxidation of the obtained allyl alcohol obtained by reducing 2-acetyl-5,8-dimethoxy-3,4-dihydronaphthalene (Sharpless et al. J.Am.Chem.Soc. 1981, 103, 6237). Another method for obtaining the optically pure tetraline consists in the stereoselective reduction of the racemic mixture with bakers' yeast to diastereoisomeric diols mixtures followed by chromatographic separation and re-oxidation (Terashima et al., Chem. Pharm. Bull. 1984, 32, 4328).

An asymmetric synthesis of the tetraline I starting from precursor III by enantioselective dihydroxylation is described in M. Nakajima et al. Tetrahedron, 1993, 49, 10807, but the several steps and the final excess of tetraline I and especially the use of osmium tetroxide in stoichiometric quantities, instead of catalytic, quantities and the use of expensive chiral amines (always in stoichiometric quantities) quantities at a temperature of - 110°C, makes very difficult the industrial use of this synthesis.

Other asymmetric synthesis of AB synthon using chiral compounds or compounds comprising chiral derivatives of natural compounds are reported in literature but all these synthesis are very complex and unsuitable for industrial application (Krohn, Angew. Chem. Int. Ed. Engl., 1986, 25, 790).

Summary of the invention


The present invention describes a process for the preparation of anthracyclines of formula VIII as above defined VIII wherein the optically active tetraline of formula I as above defined is stereoselectively prepared starting from 5,8-dialkoxy-3,4-dihydronaphthalene II which, contrary to the methods applying the resolution of racemic mixture, which are difficult to perform, and give yields inferior to 30%,

shows the advantage of giving the key intermediate I in yields much higher than those reported in literature and is easily industrially exploitable .

In particular, although the literature reported as fruitless, or non interesting because of the low yields, the attempts of acylating compound II (Rama Rao et al. 5 Ind.J.Chem.1985, 24B, 697, Russell et al. J. Chem. Soc. Chem. Comm. 1983, 994, Giles et al. S.Afr.J.Chem, 1990,43, 87), the 5,8-dialkoxy-3,4-dihydronaphthalene (compound of formula II wherein R is a group C₁₋₃ alkyl, preferably methyl) can surprisingly be acylated in just one step in the presence of an acyl chloride and aluminium trichloride forming the corresponding acyl 10 derivative III. Moreover this innovative application of the procedure of enantioselective catalytic dihydroxylation of olefins (Sharpless et al., Chem. Rev. 1994, 94, 2483) to give the insature acyl derivative allows to obtain the optically active diol IV in a good yield. The compound is thereafter converted into the corresponding 1-chloro-2-acetyl-derivative by Sharpless procedure (Sharpless et 15 al, Tetrahedron, 1992, 48, 10515) and dehalogenated following known methods, for example by catalytic hydrogenation or in the presence of tin and a radical precursor or can be directly dehydroxylated by catalytic reduction. The final hydrolysis of the ester group allows the formation of compound I in good yields and high optical purity.


5a

The present invention provides a process for the preparation of anthracycline of formula VIII:




(VIII)

wherein $R_1 = \text{H, OH, OCH}_3$; $R_2 = \text{H, OH}$; $R_3 = \text{X, Y or Z}$ where:



comprising the formation of the intermediate of formula (I):




(I)

wherein: $R = \text{C}_{1-3}$, alkyl

characterised in that said intermediate of formula (I) is prepared starting from a 5-dialkoxy-3,4-dihydronaphthalene of formula (II):


5b



wherein R = C₁₋₃ alkyl


according to the following steps:

- 5 a) the 5,8-dialkoxy-3,4-dihydronaphthalene of formula (II), is acylated in a single step with acetyl chloride in the presence of an excess of AlCl₃ at a temperature comprised between -35° and 25° C , forming the corresponding acyl derivative (III)



wherein R = C₁₋₃ alkyl;


- 10 b) the acyl derivative (III) is enantioselectively hydroxylated by a Sharpless asymmetric dihydroxylation, with a catalytic quantity of osmium, to form the diol (IV)



wherein R = C₁₋₃ alkyl;


- 15 c) the diol (IV) is converted into the acetate (VI)

5c



(VI)

by direct catalytic reduction or, alternatively, through the chloroacetate (V)



(V)

by reaction with trimethylorthoacetate in the presence of an acid catalyst followed by treatment with trimethylsilylchloride and subsequent reduction according to known procedures;

d) the acetate (VI) is hydrolyzed to the tetralin of formula (I).

Detailed description of the invention

In Schema I it is reported a process for obtaining the tetraline of formula I wherein $R = CH_3$. In this case the starting product is the 5,8-dimethoxy-3,4-dihydronaphthalene II, obtained by known methods starting from butadiene and p-quinone (Fieser et al., J.Am.Chem.Soc., 1948, 70, 3151).

In spite of the fact that in literature the attempts of acylating the compound II were reported as fruitless or non interesting because of the low yields, the 5,8-dimethoxy-3,4-dihydronaphthalene II is treated with acetyl chloride in the presence of an excess of aluminium trichloride, preferably 5 – 9 moles of aluminium trichloride for one mole of acyl chloride, at the temperature of $-35^\circ \div 25^\circ\text{C}$, preferably at 0°C . After the usual work-up and crystallisation with ethyl acetate, the product, 2-acetyl-5,8-dimethoxy-3,4-dihydronaphthalene is obtained in yields higher than 70%.

Compound III is stereoselectively converted to diol IV by a Sharpless asymmetric dihydroxylation which is described in literature for other olefin substrates (Sharpless et al., Chem. Rev. 1994, 94, 2483). The reactive used in this step is AD-mix α (catalogue Aldrich, reactive 39275-8, see also J. Org. Chem. 1992, 57, 2768) with a further addition of the osmium salt ($K_2OsO_2(OH)_4$) and methanesulphonamide.

The osmium salt is always in catalytic quantity vis-à-vis the substrate. The reaction is performed at low temperature, -4 e $+20^\circ C$, preferably at $0^\circ C$, the yield is 70%, with an enantiomeric excess higher than 95%.

The optically active diol IV is converted into a chloroacetate V through the formation "in situ" of a cyclic intermediate using trimethylorthoacetate in the presence of an acid catalyst followed by treatment with trimethylsilyl chloride according to a method already described in literature for different dioles (Sharpless et al. Tetrahedron, 1992, 48, 10515).

This step gives yields higher than 80%.

The reduction of the chloroacetate to acetate VI can be performed photochemical or by thermic treatment in the presence of tributyltinhydride and radical precursors as AIBN or BPO or by catalytic hydrogenation.

The yields are higher than 80%.

The acetate can be obtained directly by catalytic reduction of diol IV.

The hydrolysis of the acetate can be performed with ionic exchange resins in quantitative yield. Alternatively the known methods for the hydrolysis of the acetates, as the treatment with sodium methoxide or sodium hydroxide.

What reported in Scheme I can be easily applied to the synthesis of all the compounds of formula I, using the corresponding starting products.

The tetraline I which is an object of the present invention is therefore obtained in only 4-5 steps with a total yield much higher than the one reported for the known processes.

Moreover, the reaction conditions as described make it possible the industrial scale up of the process. The subsequent steps of the process through the anthracyclinone to the final anthracycline are performed as described in literature.

The process according to the invention will be better understood in the light of the hereinafter reported Example which refers to the Scheme 1 i.e. to the preparation of the tetraline of formula I wherein $R = CH_3$.

EXAMPLE 1

5 Synthesis of III

To a suspension of aluminium trichloride (449 g) in dichloromethane (2 l) in nitrogen current, acetyl chloride (380 ml) is added drop by drop at 0°C. After 30 min. stirring at 0°C, to the so obtained solution a solution of 5,8-dimethoxy-3,4-dihydronaphthalene II (80 g) in dichloromethane (2,5 l) is slowly added drop by
10 drop. After 30 min stirring at 0°C the mixture was hydrolysed with ice. After separation of the organic phase and washing with HCl 1N (3 x 6 l), H₂O (3 x 4l) and brine (2 x 4 l), the solvent was evaporated u.v. at 40°C giving a yellow solid residue (98 g). By crystallisation from refluxing ethyl acetate 71 g of the desired compound III where obtained.

15 Yield 73 %.

¹H NMR (CDCl₃): 2.44 (s, 3H, H₁₀); 2.53 (m, 2H, H₆); 2.80 (m, 2H, H₅); 3.30, 3.84 (2s, 6H, OCH₃); 6.75 (dd, 2H, H₂ + H₃); 7.81 (m, 1H, H₈);

¹³C NMR (CDCl₃): 19.9, 20.5 (C₅, C₆); 25.3 (C₁₀); 55.9, 56.1 (OCH₃); 108.5, 113.2 (C₂, C₃); 122.6, 127.2 (C_{4a}, C_{8a}); 131.5 (C₈); 137.2 (C₇); 150.4, 151.0 (C₁, C₄);
20 198.8 (C₉).

TLC: r.f. 0.80 (Petrol ether/Ethyl acetate = 80/20).

HPLC: r.t. = 8.9 min (Conditions: Lichrospher 100 RP 18 (5µm, 250 x 4 mm) CH₃CN / H₂O + 0.1 % TFA = 60 / 40; 1 ml/min; λ = 214 nm; 20 µl of a solution 1 mg/10ml)

25 EXAMPLE 2

Synthesis of IV

To a solution of AD mix-α (600 g) and K₂OsO₂(OH)₄ (1 g) in water (2 l) *t*-butanole (2.15 l), methansulphonamide (40.7 g), sodium bicarbonate (109 g) are added. The mixture was stirred up to complete solution of the solid components, cooled
30 down at 0°C, added with 4-acetyl-3,4-dihydronaphthalene (100 g) and vigorously stirred for 96 h.

After complete reaction of the precursor, checked by TLC (Petrol ether/ethyl acetate = 80/20), 630 g of sodium bisulphite are added in portions and, after 1 h stirring, 4 l of AcOEt are added and the phases are separated.

The organic phase was washed with NaOH 1N (1 x 2 l), H₂O (1 x 2 l) and
5 evaporated under vacuum.

The obtained solid was solved in 750 ml CH₂Cl₂ and the solution was extracted with H₂SO₄ 3 % saturated with K₂SO₄ (4 x 200 ml), NaHCO₃ s.s. (1 x 300 ml) and H₂O (1 x 300 ml).

The organic phase, dried on anhydrous MgSO₄, was evaporated under vacuum
10 leaving a solid residue.

The product was crystallised from AcOEt / cyclohexane = 1/1, filtered and dried under vacuum.

78.7 g of a crystalline solid were obtained. Yield: 70.5%

¹H NMR (CDCl₃): 1.87 (m, 2H, H₆); 2.38 (s, 3H, H₁₀); 2.79 (m, 2H, H₅); 3.78, 3.84
15 (2s, 6H, OCH₃); 3.81 (m, 1H, H₈); 4.87 (d, 1H, OH₈); 5.29 (s, 1H, OH₇); 6.71 (s, 2H, H₂ + H₃).

¹³C NMR (CDCl₃): 19.1 (C₁₀); 25.8 (C₅); 28.7 (C₆); 55.7, 55.7 (OCH₃); 68.5 (C₈); 78.7 (C₇); 108.0, 108.8 (C₂, C₃); 125.8, 127.1 (C_{4a}, C_{8a}); 151.1, 152.3 (C₁, C₄); 214.2 (C₉).

20 TLC: r.f. 0.25 (Petrol ether/Ethyl acetate = 80/20)

HPLC: r.t. = 4.1min (Conditions: Lichrospher 100 RP 18 (5µm) 250 x 4 mm CH₃CN / H₂O + 0.1 % TFA = 50 / 50; 1 ml/min; λ = 214 nm; 20 µl of a solution 2.8 mg/10ml)

e.e. = 98 % determined by chiral HPLC (Conditions: Chiralcel OD 250 X 4.6 mm; n-hexane / EtOH = 90 / 10; 1 ml/min; λ = 214 nm; 20 µl of a solution 1.3 mg / 10 ml)
25

m. p. = 141-143°C.

[α]_D²⁵ = -21.9° (c = 1.0, CHCl₃)

EXAMPLE 3

Synthesis of V

To a solution of diol (77 g) in CH_2Cl_2 (600 ml), under nitrogen, trimethylorthoacetate (59.3 ml) and piridiniumtoluene-4-sulphonate (2 g) are added.

5 The solution is stirred at room temperature for 24 h. The solvent is evaporated under vacuum leaving a solid residue.

The solid was solubilised CH_2Cl_2 (600 ml) and added, under nitrogen, with trimethylsilyl chloride (65 ml). The reaction mixture is stirred at room temperature for 1 h and, after evaporation of the solvent under vacuum, was treated with
10 cyclohexane (400 ml) under vigorous stirring for 3 h.

The solid was filtered and dried under vacuum.

98.1 g of the desired product were obtained (quantitative yield).

^1H NMR (CDCl_3): 1.96 (s, 3H, H_{10}); 1.97 – 3.15 (m, 4H, $\text{H}_5 + \text{H}_6$); 2.43 (s, 3H, H_{12}); 3.81, 3.87 (2s, 6H, OCH_3); 5.35 (d, 1H, H_8); 6.76 (dd, 2H, $\text{H}_2 + \text{H}_3$);

15 ^{13}C NMR (CDCl_3): 19.6 (C_{11}); 20.2, 20.5 (C_5 , C_6); 26.3 (C_{12}); 52.9 (C_8); 55.6, 56.0 (OCH_3); 82.9 (C_7); 108.3, 110.1 (C_2 , C_3); 123.2, 125.4 (C_{4a} , C_{8a}); 150.7, 151.6 (C_1 , C_4); 169.6 (C_{11}); 204.2 (C_9).

TLC : r.f. = 0.55 (Petrol ether / AcOEt = 75 / 25)

m.p. = 128-138°C.

20 $[\alpha]_D^{25} = -16.2^\circ$ (c = 1.0, CH_2Cl_2).

EXAMPLE 4

Synthesis of VI

To a solution of chloacetate (97.3 g) in toluene (2 l) AIBN (1.5 g) and tributyltinhydruce (225 ml) were added in nitrogen current. The mixture was stirred under
25 the light of a 200 Watt wolfram lamp for 24 h and thereafter extracted with water (500 ml). The organic phase is separated, dried and evaporated under vacuum. The residue is treated with cyclohexane (500 ml) under stirring, filtered and dried under vacuum at 40°C.

67.8 g of the desired product are obtained in the form of a white solid.

30 Yield : 80.3 %.

^1H NMR (CDCl_3): 1.95, 2.50 (2m, 2H, H_6); 2.05 (1.3H, H_{10}); 2.22 (1.3H, H_{12}); 2.40, 2.90 (2m, 2H, H_5); 3.00 (dd, 2H, H_8); 3.77, 3.80 (2s, 6H, OCH_3); 6.66 (m, 2H, $\text{H}_2 + \text{H}_3$).

^{13}C NMR (CDCl_3): 19.5, 21.0 (C_5 , C_6); 24.0 (C_{10}); 26.7 (C_{12}); 30.2 (C_8); 55.6, 55.5 (5) (OCH_3); 83.6 (C_7); 107.0, 107.2 (C_2 , C_3); 122.7, 125.1 (C_{4a} , C_{8a}); 150.9, 151.4 (C_1 , C_4); 170.5 (C_{11}); 206.5 (C_9).

TLC : r.f. = 0.28 (Toluene/Ethylacetate = 95/5)

HPLC: r.t. = 7.4 min (Conditions: Lichrospher 100 RP 18 (5 μm) 250 x 4 mm, $\text{CH}_3\text{CN} / \text{H}_2\text{O} + 0.1\%$ TFA = 60 / 40; 1 ml/min; $\lambda = 214$ nm; 20 μl of a solution 1.2

10 mg / 10 ml)

m.p.: 110-118°C.

$[\alpha]_D^{25}$: -46.3° (c = 1.0, CHCl_3).

EXAMPLE 5

Synthesis of I

15 To a solution of acetate (66 g) in methanol (5 l) the Amberlite IRA-400 resin (OH) (183 ml) previously activated by treatment with NaOH 30% (8 x 400 ml) and washed with water (5 x 400 ml) and methanol (4 x 400 ml) was added. The reaction mixture is stirred for a night at room temperature. After removal of the resin by filtration and evaporation of the solvent under vacuum a solid residue was
20 obtained which after crystallisation from cyclohexane/ethylacetate, filtration and drying gave 51.85 g of desired product.

Yield: 92 % .

^1H NMR (CDCl_3): 1.89 (m, 2H, H_6); 2.33 (s, 3H, H_{10}); 2.91 (m, 4H, $\text{H}_5 + \text{H}_8$); 3.65 (s, 1H, OH); 3.77, 3.80 (2s, 6H, OCH_3); 6.66 (s, 2H, $\text{H}_2 + \text{H}_3$).

25 ^{13}C NMR (CDCl_3): 19.2 (C_5); 23.9 (C_{10}); 29.7, 32.4 (C_6 , C_8); 55.5, 55.6 (OCH_3); 76.4 (C_7); 107.0, 107.4 (C_2 , C_3); 122.7, 125.5 (C_{4a} , C_{8a}); 151.1, 151.6 (C_1 , C_4); 212.3 (C_9).


TLC: r.f. = 0.27 (Petrol ether/Ethylacetate = 80/20)

HPLC : r.t. = 5.9 min (Conditions: Lichrospher 100 RP 18 (5 μm) 250 x 4 mm,
30 $\text{CH}_3\text{CN} / \text{H}_2\text{O} + 0.1\%$ TFA = 50 / 50; 1 ml/min; $\lambda = 214$ nm; 20 μl of a solution 2.5 mg/ml)

e.e = > 99% determined by chiral HPLC (Conditions: Chiralcel OD 250 X 4.6 mm; *n*-hexane / EtOH = 90 / 10; 1 ml/min; λ = 214 nm; 20 μ l of a solution 1.35 mg / 10 ml)

m.p. : 126-129°C.


5 $[\alpha]_D^{25} = -46.2^\circ$ (c = 1.0, CHCl₃)



SCHEME I

Claims


1. Process for the preparation of anthracycline of formula VIII:



5


(VIII)

wherein $R_1 = H, OH, OCH_3$; $R_2 = H, OH$; $R_3 = X, Y$ or Z where:



10


comprising the formation of the intermediate of formula (I):



(I)

15 wherein: $R = C_{1-3}$, alkyl


characterised in that said intermediate of formula (I) is prepared starting from a 5-dialkoxy-3,4-dihydronaphthalene of formula (II):



wherein R = C₁₋₃ alkyl


according to the following steps:

- 5 a) the 5,8-dialkoxy-3,4-dihydronaphthalene of formula (II), is acylated in a single step with acetyl chloride in the presence of an excess of AlCl₃ at a temperature comprised between -35° and 25° C, forming the corresponding acyl derivative (III)




wherein R = C₁₋₃ alkyl;

- 10 b) the acyl derivative (III) is enantioselectively hydroxylated by a Sharpless asymmetric dihydroxylation, with a catalytic quantity of osmium, to form the diol (IV)




wherein R = C₁₋₃ alkyl;

- 15 c) the diol (IV) is converted into the acetate (VI)



(VI)

by direct catalytic reduction or, alternatively, through the chloroacetate (V)




(V)

- 5 by reaction with trimethylorthoacetate in the presence of an acid catalyst followed by treatment with trimethylsilylchloride and subsequent reduction according to known procedures;

d) the acetate (VI) is hydrolized to the tetralin of formula (I).

2. Process according to claim 1 wherein the tetralin of formula (I) is converted,
10 according to known procedures, into the anthracyclinone of formula (VII),



VII

- wherein $R_1 = H, OH, OCH_3$, $R_2 = H, OH, O\text{-acyl}$, wherein acyl is chosen between
15 formyl, acetyl, mono- or di-chloroacetyl
and this is finally converted into the anthracicline of formula (VIII) as defined in Claim 1 according to known procedures.

3. Process according to claim 2 wherein $R = \text{methyl}$ and $R_2 = O\text{-acetyl}$.
4. Process according to claim 1 wherein the acylation is performed at 0°C .
20 5. Process according to claim 1 wherein the enantioselective dihydroxylation according to step (b) is performed using catalytic quantities of osmium using the

reactive AD-mix α with a further addition of an osmium salt and methanesulphonamide.


6. Process according to claim 5 wherein the osmium salt used is $K_2OsO_2(OH)_4$.

7. Process according to claim 6 wherein the reaction is performed at $-4 - +20^\circ C$.

5 8. Process according to claim 7 wherein the reaction is performed at $0^\circ C$.

9. Process according to claims 1 – 8 wherein the anthracyclines of formula (VIII) are: daunomicin (VIII, wherein $R_1 = OCH_3$, $R_2 = H$, $R_3 = X$), doxorubicin (VIII wherein: $R_1 = OCH_3$, $R_2 = OH$, $R_3 = X$), l'hydrarubicin (VIII wherein: $R_1 = H$, $R_2 = H$, $R_3 = X$) l'epirubicin (VIII, wherein: $R_1 = OCH_3$, $R_2 = OH$, $R_3 = Y$), or a tetracycline of
10 formula VIII wherein: $R_1 = H$, $R_2 = OH$, $R_3 = Z$, where X, Y and Z are as defined in claim 1.

10. Optically active compound of formula V



(V)